Rapamycin resistant cells

Patent metadata

Field	Value
Publication number	US-12595492-B2
Application number	US-202418631675-A
Country	US
Kind code	B2
Filing date	Apr 10, 2024
Priority date	Apr 27, 2018
Publication date	Apr 7, 2026
Grant date	Apr 7, 2026

Abstract

The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

First claim

What is claimed is:

1 . A cell prepared by introducing into a cell:
(i) a first polynucleotide encoding a soluble FK506-binding protein (FKBP)-rapamycin-binding (FRB) domain polypeptide; (ii) a second polynucleotide encoding a first chemically induced signaling complex (CISC) component, wherein the first CISC component comprises a first extracellular binding domain comprising an FKBP domain, a first transmembrane domain, and a first cytoplasmic signaling domain; and (iii) a third polynucleotide encoding a second CISC component, wherein the second CISC component comprises a second extracellular binding domain comprising an FRB domain, a second transmembrane domain, and a second cytoplasmic signaling domain; and wherein the first CISC component and the second CISC component dimerize in the presence of a ligand to create a signaling-competent CISC.

2 . The cell of claim 1 , further comprising a DNA endonuclease or a fourth polynucleotide encoding the DNA endonuclease.

3 . The cell of claim 2 , further comprising a guide RNA (gRNA) or a fifth polynucleotide encoding the gRNA, wherein the gRNA comprises a spacer sequence that is complementary to a target sequence in a target genomic locus.

4 . A cell comprising:
(i) a first polynucleotide encoding a soluble FK506-binding protein (FKBP)-rapamycin-binding (FRB) domain polypeptide; or the soluble FRB domain polypeptide; (ii) a second polynucleotide encoding a first chemically induced signaling complex (CISC) component, wherein the first CISC component comprises a first extracellular binding domain comprising an FKBP domain, a first transmembrane domain, and a first cytoplasmic signaling domain; or the first CISC component; and (iii) a third polynucleotide encoding a second CISC component, wherein the second CISC component comprises a second extracellular binding domain comprising an FRB domain, a second transmembrane domain, and a second cytoplasmic signaling domain; or the second CISC component; and wherein the first CISC component and the second CISC component dimerize in the presence of a ligand to create a signaling-competent CISC.

5 . The cell of claim 4 , wherein the soluble FRB domain polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 1.

6 . The cell of claim 5 , wherein the soluble FRB domain polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or 2.

7 . The cell of claim 4 , wherein the ligand is rapamycin or a rapalog.

8 . The cell of claim 7 , wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, AP23573, a metabolite of rapamycin, and an IMID-class drug.

9 . The cell of claim 4 , wherein:
(a) the first cytoplasmic signaling domain comprises an IL-2 receptor subunit gamma (IL-2Rγ) cytoplasmic domain and the second cytoplasmic signaling domain comprises an IL-2 receptor subunit beta (IL-2Rβ) cytoplasmic domain; or (b) the second cytoplasmic signaling domain comprises the IL-2Rγ cytoplasmic domain and the first cytoplasmic signaling domain comprises the IL-2Rβ cytoplasmic domain.

10 . The cell of claim 9 , wherein the IL-2Rβ cytoplasmic domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 5.

11 . The cell of claim 9 , wherein the second cytoplasmic signaling domain comprises the IL-2Rβ cytoplasmic domain, wherein the second CISC component comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 7.

12 . The cell of claim 4 , wherein the FKBP domain of the first extracellular binding domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 6.

13 . The cell of claim 4 , wherein the FRB domain of the second extracellular binding domain comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1.

14 . The cell of claim 4 , wherein the first CISC component comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 12.

15 . The cell of claim 4 , wherein the second CISC component comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 13.

16 . The cell of claim 4 , wherein
(i) the first CISC component comprises, in N-to-C-terminal order:
(a) the FKBP domain;
(b) an IL-2 receptor subunit gamma (IL-2Rγ) transmembrane domain; and
(c) an IL-2Rγ cytoplasmic domain; and
(ii) the second CISC component comprises, in N-to-C-terminal order:
(a) the FRB domain;
(b) an IL-2 receptor subunit beta (IL-2Rβ) transmembrane domain; and
(c) an IL-2Rβ cytoplasmic domain.

17 . The cell of claim 16 , wherein the first CISC component comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 12, and the second CISC component comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 13.

18 . The cell of claim 4 , wherein the cell is a T cell, B cell or a natural killer (NK) cell.

19 . The cell of claim 4 , wherein the cell is a hematopoietic stem cell.

20 . The cell of claim 4 , wherein the cell is a precursor T cell or a T regulatory (Treg) cell.

21 . The cell of claim 20 , wherein the cell is a CD4+ T helper lymphocyte cell selected from the group consisting of naive CD4+ T cells, central memory CD4+ T cells, effector memory CD4+ T cells, and bulk CD4+ T cells.

22 . The cell of claim 20 , wherein the cell is a CD8+ T cytotoxic lymphocyte cell selected from the group consisting of naive CD8+ T cells, central memory CD8+ T cells, effector memory CD8+ T cells, and bulk CD8+ T cells.

23 . A method for preparing a cell, comprising introducing into a cell:
(i) a first polynucleotide encoding a soluble FK506-binding protein (FKBP)-rapamycin-binding (FRB) domain polypeptide or the soluble FRB domain polypeptide; (ii) a second polynucleotide encoding a first chemically induced signaling complex (CISC) component, wherein the first CISC component comprises a first extracellular binding domain comprising an FKBP domain, a first transmembrane domain, and a first cytoplasmic signaling domain; and (iii) a third polynucleotide encoding a second CISC component, wherein the second CISC component comprises a second extracellular binding domain comprising an FRB domain, a second transmembrane domain, and a second cytoplasmic signaling domain; and wherein the first CISC component and the second CISC component dimerize in the presence of a ligand to create a signaling-competent CISC.

24 . The method of claim 23 , wherein the soluble FRB domain polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 1.

25 . The method of claim 23 , further comprising contacting the cell with the ligand.

26 . The method of claim 25 , wherein the ligand is rapamycin or a rapalog.

27 . The method of claim 26 , wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, AP23573, a metabolite of rapamycin, and an IMID-class drug.

28 . The method of claim 23 , wherein:
(a) the first cytoplasmic signaling domain

Assignees

• Seattle Childrens Hospital

Inventors

• Scharenberg Andrew M
• Rawlings David J
• Sommer Karen
• West Samuel
• Honaker Yuchi Chiang
• Takeuchi Ryo

Classifications

• A61K40/418

  Antigens related to induction of tolerance to non-self · CPC title

• A61K40/416

  Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title

• A61K40/22

  Immunosuppressive or immunotolerising · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title